Feb 20, 6:51 PM EST
Everything You Need To Know, Right Now.
Stay connected to the biggest stories unfolding in technology.
The IBTech Newsletter keeps you connected to the biggest stories unfolding in technology.
Please enter a valid email
Media & Culture
FDA Approves Synthetic Surfactant to Treat Life-Threatening Condition in Pre-Term Babies
on 03/14/12 AT 3:10 AM
The Food and Drug Administration (FDA) has approved Surfaxin (lucinactant) to treat Respiratory Distress Syndrome (RDS), a life-threatening condition affecting pre-term babies.